Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 April 2005, Vol. 105, No. 8, pp. 3263-3269.
Prepublished online as a Blood First Edition Paper on December 21, 2004; DOI 10.1182/blood-2004-07-2752.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-07-2752v1
105/8/3263    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grimm, T.
Right arrow Articles by Sturzl, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grimm, T.
Right arrow Articles by Sturzl, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted July 19, 2004
Accepted December 11, 2004

EBV latent membrane protein-1 protects B-cells from apoptosis by inhibition of bax

Thomas Grimm, Sabine Schneider, Elisabeth Naschberger, Jurgen Huber, Eric Guenzi, Arnd Kieser, Peter Reitmeir, Thomas F Schulz, Cindy A Morris, and Michael Sturzl*

Department of Virus-induced Vasculopathy, GSF-National Research Center for Environment and Health, Institute of Molecular Virology, Neuherberg, Germany
Department of Surgery, Division of Molecular and Experimental Surgery, University of Erlangen-Nurnberg, Erlangen, Germany
Department of Gene Vectors, GSF-National Research Center for Environment and Health, Institute of Clinical Molecular Biology and Tumor Genetics, Munich, Germany
Institute of Health Economics and Health Care Management, GSF-National Research Center for Environment and Health, Neuherberg, Germany
Department of Virology, Medical School Hannover, Hannover, Germany
Department of Microbiology and Immunology, Tulane University Health Service Center, New Orleans, LA, USA
Department of Virus-induced Vasculopathy, GSF-National Research Center for Environment and Health, Institute of Molecular Virology, Neuherberg, Germany; Department of Surgery, Division of Molecular and Experimental Surgery, University of Erlangen-Nurnberg, Erlangen, Germany

* Corresponding author; email: michael.stuerzl{at}chir.imed.uni-erlangen.de.

Latent membrane protein (LMP)-1 of Epstein-Barr virus (EBV) promotes tumorigenesis by inhibiting apoptosis. We show that an important anti-apoptotic activity of LMP-1 is the inhibition of Bax, a potent pro-apoptotic protein. Bax expression was regulated by LMP-1 activation of NF-{kappa}B via the C-terminal activation regions (CTARs) -1 and -2. Interestingly, p65/p50 inhibited whereas p50/p50 increased bax promoter activity as demonstrated by overexpression and selective inhibition of these NF-{kappa}B isoforms. Electrophoretic mobility shift analysis revealed that LMP-1 activates two of the three NF-kB binding sites ({kappa}B1-{kappa}B3) in the bax promoter. LMP-1 induced binding of the NF-{kappa}B heterodimer p65/p50 to the {kappa}B2 site and of the p50/p50 homodimer to the {kappa}B3 site. Promoter mutation analysis revealed that the {kappa}B2 site is necessary for inhibition of bax promoter activity, and the kB3 site for its activation. However, the activation of the bax promoter by LMP-1 was only observed in the presence of specific inhibitors of p65/p50. In all other cases LMP-1 inhibited bax promoter activity. Most importantly, the anti-apoptotic activity of LMP-1 was considerably decreased in cells deficient for bax. These results indicate that the inhibition of bax may be an important anti-apoptotic activity of LMP-1.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
C. Le Clorennec, T.-S. Ouk, I. Youlyouz-Marfak, S. Panteix, C.-C. Martin, J. Rastelli, E. Adriaenssens, U. Zimber-Strobl, J. Coll, J. Feuillard, et al.
Molecular Basis of Cytotoxicity of Epstein-Barr Virus (EBV) Latent Membrane Protein 1 (LMP1) in EBV Latency III B Cells: LMP1 Induces Type II Ligand-Independent Autoactivation of CD95/Fas with Caspase 8-Mediated Apoptosis
J. Virol., July 1, 2008; 82(13): 6721 - 6733.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H.-C. Chuang, J.-D. Lay, S.-E. Chuang, W.-C. Hsieh, Y. Chang, and I.-J. Su
Epstein-Barr Virus (EBV) Latent Membrane Protein-1 Down-Regulates Tumor Necrosis Factor-{alpha} (TNF-{alpha}) Receptor-1 and Confers Resistance to TNF-{alpha}-Induced Apoptosis in T Cells: Implication for the Progression to T-Cell Lymphoma in EBV-Associated Hemophagocytic Syndrome
Am. J. Pathol., May 1, 2007; 170(5): 1607 - 1617.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
G. Goormachtigh, T.-S. Ouk, A. Mougel, D. Tranchand-Bunel, E. Masy, C. Le Clorennec, J. Feuillard, G. W. Bornkamm, C. Auriault, E. Manet, et al.
Autoactivation of the Epstein-Barr Virus Oncogenic Protein LMP1 during Type II Latency through Opposite Roles of the NF-{kappa}B and JNK Signaling Pathways.
J. Virol., August 1, 2006; 80(15): 7382 - 7393.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Sors, F. Jean-Louis, C. Pellet, L. Laroche, L. Dubertret, G. Courtois, H. Bachelez, and L. Michel
Down-regulating constitutive activation of the NF-{kappa}B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis
Blood, March 15, 2006; 107(6): 2354 - 2363.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020